Going public wasn't easy for Bioheart. After delaying its IPO twice and slashing its prospective share price from a range of $14 to $16 to $6 to $8, the Sunrise, FL-based biotech saw its share price quickly slip from its $5.25 a share offering on its first day of trading on Tuesday. The biotech raised about $5.8 million in a tough market. Much of that money will go to funding clinical trials of its cell therapy for heart damage. Release [1] | Report [2]
Links:
[1] http://www.fiercebiotech.com/press-releases/bioheart-announces-pricing-initial-public-offering-and-commencement-trading
[2] http://www.forbes.com/feeds/ap/2008/02/19/ap4671357.html?dlbk